• Facebook
  • X
  • Instagram
  • Contact Us
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page
BMS/Celgene Called Out by House Oversight Committee on Drug Pricing of Revlemid

BMS/Celgene Called Out by House Oversight Committee on Drug Pricing of Revlemid

by MM360 Staff Writer | Oct 1, 2020 | Featured News, Myeloma News

House Oversight Committee hold hearings on drug Pricing. The Committee is holding two days of hearings with top executives of major drug companies to examine their pricing practices for some of the costliest drugs in the United States.  The hearings, titled...
ONCOTracker and the Binding Site Collaborate to Develop sBCMA Monitoring Test

ONCOTracker and the Binding Site Collaborate to Develop sBCMA Monitoring Test

by MM360 Staff Writer | Sep 28, 2020 | Featured News, Myeloma News

ONCOTracker and The Binding Site have entered an agreement to develop and commercialize a new test that measures serum levels of the B-cell maturation antigen (sBCMA) protein to monitor people with blood cancers, including multiple myeloma.  Serum B-cell maturation...
Ide-cel (Anti-BCMA CAR T Cell Therapy) Granted FDA Priority Review for Heavily-treated Multiple Myeloma

Ide-cel (Anti-BCMA CAR T Cell Therapy) Granted FDA Priority Review for Heavily-treated Multiple Myeloma

by MM360 Staff Writer | Sep 22, 2020 | Featured News, Myeloma News

FDA set a target action date of March 27, 2021 Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma Bristol Myers Squibb and bluebird bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority...

Infections Cause 22% of Deaths in Multiple Myeloma

by MM360 Staff Writer | Feb 28, 2018 | Featured News, Myeloma News

A Swedish study published in Haematologica suggests that infections are a major cause of morbidity and mortality in patients with multiple myeloma.  The population-based study of 9253 patients showed that  infection caused 22% of deaths in patients diagnosed...

Recent Content

  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Triplet regimen extends OS in relapsed or refractory multiple myeloma
  • Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
  • Contact Us
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT